Jaspreet Kalra, PhD
Postdoctoral Scholar
Cardiovascular Research Inst
School of Medicine

I am interested in studying cardiovascular diseases aimed at unraveling the molecular pathways involved in progression and development of hypertension. Contraction-relaxation cycle in smooth muscle cells and in in-vivo models involved in blood pressure regulation.

Awards

Show all (4) Hide

• American Heart Institution, University of Virginia and University of California San Francisco, 2022-2024
• Best Oral presenter Global Health summit ICONICA 2020, Punjab University Chandigarh India, BITS Pilani, Hyderabad Campus, India, 2020
• DST-International Travel Grant, BITS-Pilani, Hyderabad Campus, India, 2020
• Council of Scientific and Industrial Research-HRDG, India, BITS-Pilani, Hyderabad Campus, India, 2018-2020

Education & Training

Show all (5) Hide

• Postdoctoral Training Molecular Physiology and Cardiovascular Pharmacology University of Virginia, Charlottesville 07/2023
• PhD Cardiovascular Pharmacology BITS Pilani, Hyderabad Campus 02/2021
• M.Pharm Pharmacology ISF College of Pharmacy, Moga, Punjab 09/2014
• B.Pharm Pharmaceutical Sciences SBSPGI Balawala, Dehradun 06/2012
• Postdoctoral Training Vascular Pharmacology and Biology University of California San Francisco

Interests

Show all (2) Hide

• Hypertension
• Cardiovascular Pharmacology

Publications (23)

Top publication keywords:
Visceral PainFructoseNeuroprotective AgentsImidazoleseIF-2 KinaseLipoxygenaseVascular RemodelingOxidative StressTriterpenesIndolesDiabetic CardiomyopathiesProtein Kinase InhibitorsSodium-Glucose Transporter 1Prostaglandin-Endoperoxide SynthasesCentral Nervous System Agents

• p90RSK2, a new MLCK mediates contractility in myosin light chain kinase null smooth muscle.
  Frontiers in physiology 2023 Kalra J, Artamonov M, Wang H, Franke A, Markowska Z, Jin L, Derewenda ZS, Ayon RJ, Somlyo A
• p90RSK2, a new MLCK, rescues contractility in myosin light chain kinase null smooth muscle.
  bioRxiv : the preprint server for biology 2023 Kalra J, Artamonov M, Wang H, Franke A, Markowska Z, Jin L, Derewenda ZS, Ayon R, Somlyo A
• FHL5 Controls Vascular Disease-Associated Gene Programs in Smooth Muscle Cells.
  Circulation research 2023 Wong D, Auguste G, Lino Cardenas CL, Turner AW, Chen Y, Song Y, Ma L, Perry RN, Aherrahrou R, Kuppusamy M, Yang C, Mosquera JV, Dube CJ, Khan MD, Palmore M, Kalra J, Kavousi M, Peyser PA, Matic L, …
• Crosslink between mutations in mitochondrial genes and brain disorders: implications for mitochondrial-targeted therapeutic interventions.
  Neural regeneration research 2023 Kalra J
• Publisher Correction: High fructose and streptozotocin induced diabetic impairments are mitigated by Indirubin‑3‑hydrazone via downregulation of PKR pathway in Wistar rats.
  Scientific reports 2021 Udumula MP, Mangali S, Kalra J, Dasari D, Goyal S, Krishna V, Bollareddy SR, Sriram D, Dhar A, Bhat A

Show all (18 more) Hide

• High fructose and streptozotocin induced diabetic impairments are mitigated by Indirubin-3-hydrazone via downregulation of PKR pathway in Wistar rats.
  Scientific reports 2021 Udumula MP, Mangali S, Kalra J, Dasari D, Goyal S, Krishna V, Bollareddy SR, Sriram D, Dhar A, Bhat A
• Up-regulation of PKR pathway contributes to L-NAME induced hypertension and renal damage.
  Heliyon 2020 Kalra J, Bhat A, Jadhav KB, Dhar A
• PKR inhibitor imoxin prevents hypertension, endothelial dysfunction and cardiac and vascular remodelling in L-NAME-treated rats.
  Life sciences 2020 Kalra J, Dasari D, Bhat A, Mangali S, Goyal SG, Jadhav KB, Dhar A
• Upregulation of PKR pathway mediates glucolipotoxicity induced diabetic cardiomyopathy in vivo in wistar rats and in vitro in cultured cardiomyocytes.
  Biochemical pharmacology 2020 Mangali S, Bhat A, Jadhav K, Kalra J, Sriram D, Vamsi Krishna Venuganti V, Dhar A
• SGLT1 inhibition boon or bane for diabetes-associated cardiomyopathy.
  Fundamental & clinical pharmacology 2019 Kalra J, Mangali SB, Dasari D, Bhat A, Goyal S, Dhar I, Sriram D, Dhar A
• Selective inhibition of PKR improves vascular inflammation and remodelling in high fructose treated primary vascular smooth muscle cells.
  Biochimica et biophysica acta. Molecular basis of disease 2019 Kalra J, Mangali S, Bhat A, Jadhav K, Dhar A
• Pharmacological evaluation of novel PKR inhibitor indirubin-3-hydrazone in-vitro in cardiac myocytes and in-vivo in wistar rats.
  Life sciences 2018 Udumula MP, Bhat A, Mangali S, Kalra J, Dhar I, Sriram D, Dhar A
• Imoxin attenuates high fructose-induced oxidative stress and apoptosis in renal epithelial cells via downregulation of protein kinase R pathway.
  Fundamental & clinical pharmacology 2018 Kalra J, Mangali SB, Bhat A, Dhar I, Udumula MP, Dhar A
• Betulinic acid alleviates dextran sulfate sodium-induced colitis and visceral pain in mice.
  Naunyn-Schmiedeberg's archives of pharmacology 2017 Kalra J, Lingaraju MC, Mathesh K, Kumar D, Parida S, Singh TU, Sharma AK, Kumar D, Tandan SK
• Double-stranded RNA-dependent protein kinase signalling and paradigms of cardiometabolic syndrome.
  Fundamental & clinical pharmacology 2017 Kalra J, Dhar A
• Pharmacological evaluation of novel alagebrium analogs as methylglyoxal scavengers in vitro in cardiac myocytes and in vivo in SD rats.
  International journal of cardiology 2016 Dhar A, Udumula MP, Medapi B, Bhat A, Dhar I, Malapati P, Babu MS, Kalra J, Sriram D, Desai KM
• Effect of ursolic acid in attenuating chronic constriction injury-induced neuropathic pain in rats.
  Fundamental & clinical pharmacology 2016 Bhat RA, Lingaraju MC, Pathak NN, Kalra J, Kumar D, Kumar D, Tandan SK
• Modulation of LOX and COX pathways via inhibition of amyloidogenesis contributes to mitoprotection against β-amyloid oligomer-induced toxicity in an animal model of Alzheimer's disease in rats.
  Pharmacology, biochemistry, and behavior 2016 Kalra J, Kumar P, Majeed AB, Prakash A
• Effect of Trimeric Myricetin Rhamnoside (TMR) in Carrageenan-induced Inflammation and Caecal Ligation and Puncture-induced Lung Oxidative Stress in Mice.
  Phytotherapy research : PTR 2015 Latief N, Anand S, Lingaraju MC, Balaganur V, Pathak NN, Kalra J, Kumar D, Bhadoria BK, Tandan SK
• Reducing Aβ load and tau phosphorylation: Emerging perspective for treating Alzheimer's disease.
  European journal of pharmacology 2015 Kalra J, Khan A
• Cerebroprotective effects of RAS inhibitors: Beyond their cardio-renal actions.
  Journal of the renin-angiotensin-aldosterone system : JRAAS 2015 Kalra J, Prakash A, Kumar P, Majeed AB
• Neuroprotective effect of N-acetyl cysteine against streptozotocin-induced memory dysfunction and oxidative damage in rats.
  Journal of basic and clinical physiology and pharmacology 2015 Prakash A, Kalra JK, Kumar A
• Pharmacological approaches for Alzheimer's disease: neurotransmitter as drug targets.
  Expert review of neurotherapeutics 2014 Prakash A, Kalra J, Mani V, Ramasamy K, Majeed AB